0000000000611802

AUTHOR

Francesco Menzella

showing 14 related works from this author

Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)

2020

According to the data derived from several national and international registries, including SANI (Severe Asthma Network Italy), and considering the strong impact that frequent or regular use of oral corticosteroid has on quality of life (QoL) of severe asthmatics, as well as on the costs for managing corticosteroid-related diseases, oral corticosteroid sparing up to withdrawal should be considered a primary outcome in the management of severe asthma. New biologics have clearly demonstrated that this effect is possible, with concomitant reduction in the rate of exacerbations and in symptom control. Then, there is no reason for using so frequently oral corticosteroid before having explored al…

ISAR International Severe Asthma RegistrySHARPPediatricsSevere asthmaSA severe asthmaBiologics Oral corticosteroids Real-life Registr Severe asthmaOmalizumabforced expiratory volume in the 1st secondFood &ampGrading of Recommendations Assessmentchronic rhinosinusitis with nasal polyposisFEV1chemistry.chemical_compound0302 clinical medicineQuality of lifeEMAReal WorldEuropean Medicines AgencyBiologics; Oral corticosteroids; Real-life; Registr; Severe asthmaOral corticosteroidsFDA Food & Drug AdministrationImmunology and Allergy030223 otorhinolaryngologySevere Heterogeneous Asthma Research collaborationmusculoskeletal neural and ocular physiologyReal-lifeCRSwNPOCSsBenralizumabDupilumabCRSwNP chronic rhinosinusitis with nasal polyposisGRADESHARP Severe Heterogeneous Asthma Research collaboration Patient-centredSevere Asthma Network in ItalyFDAmedicine.drugPulmonary and Respiratory Medicinelcsh:Immunologic diseases. Allergymedicine.medical_specialtyDrug AdministrationGINA Global Initiative for AsthmaRW Real WorldImmunologymacromolecular substancesRWSettore MED/10 - Malattie Dell'Apparato RespiratorioBiologicsInternational Severe Asthma RegistryISAR03 medical and health sciencesSADisease registrySARP Severe Asthma Research ProgramPatient-centredmedicineAsthmabusiness.industrySettore MED/09 - MEDICINA INTERNASANI Severe Asthma Network in ItalySANIBiological productmedicine.diseaseOCSs Oral CorticoSteroidsGINASARPSevere Asthma Research ProgramFEV1 forced expiratory volume in the 1st second030228 respiratory systemchemistrynervous systemRegistrEMA European Medicines AgencyDevelopment and EvaluationSevere asthma Biologics Oral corticosteroids Real-life Registrbusinesslcsh:RC581-607Global Initiative for AsthmaMepolizumabGRADE Grading of Recommendations Assessment Development and Evaluation
researchProduct

Validation of Murray sputum purulence scale in the Italian Registry of Bronchiectasis (IRIDE)

2018

Introduction: Murray sputum colour chart stratifies patients according to the presence of mucous (M), muco-purulent (MP) or purulent (P) sputum, and has not been validated in Bx yet. We aimed to validate this scale across a large Italian cohort of Bx patients. Methods: A secondary analysis of the IRIDE database was conducted including adults with Bx and daily sputum production enrolled across 13 Italian centres between 2014 and 2017. M vs. MP vs. P sputum producers were identified and clinical, functional and microbiological data were collected. Clinical outcomes during a two-year follow up period were evaluated in the Monza and Milan cohorts. A sensitivity analysis excluding COPD patients …

medicine.medical_specialtyBronchiectasisSputum colourCopd patientsbusiness.industrySputum Productionmedicine.diseaseDisease severityInternal medicineSecondary analysisCohortmedicineSputummedicine.symptombusiness
researchProduct

The Severe Asthma Network in Italy: Findings and Perspectives

2019

Background Severe Asthma Network in Italy (SANI) is a registry of patients recruited by accredited centers on severe asthma. Objective To analyze epidemiological, clinical, inflammatory, functional, and treatment characteristics of severe asthmatics from the SANI registry. Methods All consecutive patients with severe asthma were included into the registry, without exclusion criteria to have real-life data on demographics, asthma control, treatments (including biologics), inflammatory biomarkers, and comorbidities. Results A total of 437 patients (mean age: 54.1 years, 57.2% females, 70.7% atopics, 94.5% in Global Initiative for Asthma severity step V) were enrolled into the study. The mean …

AdultMalemedicine.medical_specialtyRegistrySevere asthmaExacerbationBronchiectasis; Comorbidities; Late-onset asthma; Nasal polyps; Registry; SANI; Severe asthma; Immunology and AllergyOmalizumabComorbiditySettore MED/10 - Malattie Dell'Apparato RespiratorioComorbiditiesAtopy03 medical and health sciencesBronchiectasi0302 clinical medicineFood allergyInternal medicineLate-onset asthmaNasal polypsBronchiectasis; Comorbidities; Late-onset asthma; Nasal polyps; Registry; SANI; Severe asthma; Adult; Aged; Asthma; Bronchiectasis; Comorbidity; Eosinophils; Female; Humans; Immunoglobulin E; Italy; Male; Middle Aged; Nasal Polyps; Registries; RhinitisMedicineHumansBronchiectasis Comorbidities Late-onset asthma Nasal polyps Registry SANI Severe asthma Immunology and AllergyImmunology and Allergy030212 general & internal medicineRegistriesAsthmaAgedRhinitisBronchiectasisbusiness.industryNasal polypSANIImmunoglobulin EMiddle Agedmedicine.diseaseAsthmaBronchiectasisEosinophils030228 respiratory systemItalyAsthma Control QuestionnaireFemaleComorbiditiebusinessMepolizumabmedicine.drug
researchProduct

Microbiological testing of adults hospitalised with community-acquired pneumonia: an international study

2018

This study aimed to describe real-life microbiological testing of adults hospitalised with community-acquired pneumonia (CAP) and to assess concordance with the 2007 Infectious Diseases Society of America (IDSA)/American Thoracic Society (ATS) and 2011 European Respiratory Society (ERS) CAP guidelines. This was a cohort study based on the Global Initiative for Methicillin-resistant Staphylococcus aureus Pneumonia (GLIMP) database, which contains point-prevalence data on adults hospitalised with CAP across 54 countries during 2015. In total, 3702 patients were included. Testing was performed in 3217 patients, and included blood culture (71.1%), sputum culture (61.8%), Legionella urinary anti…

0301 basic medicinePulmonary and Respiratory Medicinemedicine.medical_specialtycommunity-acquired pneumoniaCommunity-acquired pneumoniaPatients4Concordance030106 microbiologyRespiratory Systemlcsh:MedicineSettore MED/10 - Malattie Dell'Apparato RespiratorioGUIDELINESPneumònia adquirida a la comunitatSputum cultureSerology03 medical and health sciences0302 clinical medicineCommunity-acquired pneumoniaInternal medicinemedicineMANAGEMENTBlood culture030212 general & internal medicinePOPULATIONpneumonia Methicillin-resistant Staphylococcus aureus PneumoniaScience & Technologymedicine.diagnostic_testbusiness.industryMORTALITYlcsh:RMicrobiologia mèdicaOriginal ArticlesGuidelinePneumoniaMedical microbiologymedicine.diseaseMicrobiologicalETIOLOGYPneumoniaDiagnostic testingREQUIRING HOSPITALIZATIONbusinessLife Sciences & BiomedicineCohort studyERJ Open Research
researchProduct

Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe…

2021

Background: ANDHI was done to assess the efficacy of benralizumab, including onset of effect and impact on health-related quality of life (HRQOL), exacerbation rate, lung function, and nasal polyposis symptoms. Methods: This phase 3b, randomised, double-blind, parallel-group, placebo-controlled ANDHI study was completed in adults (aged 18–75 years) with severe eosinophilic asthma with at least 2 exacerbations in the previous year, despite high-dose inhaled corticosteroid plus additional controllers, screening blood eosinophil counts of at least 150 cells per μL, and an Asthma Control Questionnaire 6 (ACQ-6) score of 1·5 or more. Patients who met eligibility criteria were randomly assigned (…

Pulmonary and Respiratory MedicineSpirometryAdultMalemedicine.medical_specialtyExacerbation[SDV]Life Sciences [q-bio]PopulationSettore MED/10 - Malattie Dell'Apparato RespiratorioPlaceboAntibodies Monoclonal Humanized03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodInternal medicinemedicineHumans030212 general & internal medicineAnti-Asthmatic AgentsPatient Reported Outcome MeasureseducationSinusitisAsthmaeducation.field_of_studymedicine.diagnostic_testbusiness.industryMiddle Agedmedicine.diseaseBenralizumabAsthma3. Good healthEosinophils030228 respiratory systemchemistryAsthma Control QuestionnaireSpirometryDisease ProgressionQuality of LifeFemalebusiness
researchProduct

Aspiration Risk Factors, Microbiology, and Empiric Antibiotics for Patients Hospitalized With Community-Acquired Pneumonia

2021

Background: Aspiration community-acquired pneumonia (ACAP) and community-acquired pneumonia (CAP) in patients with aspiration risk factors (AspRFs) are infections associated with anaerobes, but limited evidence suggests their pathogenic role. Research Question: What are the aspiration risk factors, microbiology patterns, and empiric anti-anaerobic use in patients hospitalized with CAP? Study Design and Methods: This is a secondary analysis of GLIMP, an international, multicenter, point-prevalence study of adults hospitalized with CAP. Patients were stratified into three groups: (1) ACAP, (2) CAP/AspRF+ (CAP with AspRF), and (3) CAP/AspRF- (CAP without AspRF). Data on demographics, comorbidi…

MalePulmonary and Respiratory Medicinemedicine.drug_classAspiration riskAntibioticsNursing home residentSettore MED/10 - Malattie Dell'Apparato RespiratorioCritical Care and Intensive Care MedicineMicrobiologyanaerobic; aspiration; bacteria; pneumonia; risk factors.Cohort Studies03 medical and health sciences0302 clinical medicineCommunity-acquired pneumoniaTaverneAnti-Bacterial AgentmedicineHumanspneumoniarisk factors.Community-Acquired Infection030212 general & internal medicinebacteriaStrokeAgedAged 80 and overaspirationbusiness.industryRespiratory AspirationMiddle Agedmedicine.diseaseAntibiotic coverageAnti-Bacterial AgentsCommunity-Acquired InfectionsHospitalizationPneumonia030228 respiratory systemRisk factorsrisk factoranaerobicFemaleUnderweightmedicine.symptombusinessCardiology and Cardiovascular Medicine
researchProduct

Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients

2018

Abstract Background The correct management of immunocompromised patients with pneumonia is debated. We evaluated the prevalence, risk factors, and characteristics of immunocompromised patients coming from the community with pneumonia. Methods We conducted a secondary analysis of an international, multicenter study enrolling adult patients coming from the community with pneumonia and hospitalized in 222 hospitals in 54 countries worldwide. Risk factors for immunocompromise included AIDS, aplastic anemia, asplenia, hematological cancer, chemotherapy, neutropenia, biological drug use, lung transplantation, chronic steroid use, and solid tumor. Results At least 1 risk factor for immunocompromis…

0301 basic medicineMalePediatricsEtiologyMultidrug-resistant pathogenMRSAPneumocystis pneumoniaPneumònia adquirida a la comunitatHOSPITALIZED-PATIENTS0302 clinical medicineCommunity-acquired pneumoniaRisk FactorsPrevalenceMedicine030212 general & internal medicinePNEUMOCYSTIS PNEUMONIAArticles and CommentariesAged 80 and overRespiratory tract infectionsAnemia AplasticMiddle Aged3. Good healthCommunity-Acquired InfectionsEuropeInfectious DiseasesImmunocompromise; Microbiology; MRSA; Multidrug-resistant pathogens; PneumoniaEtiologiaHematologic NeoplasmsFemaleBLOOD-STREAM INFECTIONSLung TransplantationMicrobiology (medical)medicine.medical_specialtyAsiaNeutropeniaCommunity-acquired pneumonia030106 microbiologyRESPIRATORY-TRACT INFECTIONSHematologic NeoplasmsSettore MED/10 - Malattie Dell'Apparato RespiratorioTRANSPLANT RECIPIENTSDISEASES-SOCIETYMicrobiology03 medical and health sciencesImmunocompromised HostPneumonia BacterialMANAGEMENTHumanspneumoniaBACTERIAL PNEUMONIAImmunocompromiseAgedAcquired Immunodeficiency Syndromebusiness.industrymicrobiologyBacterial pneumoniaAustraliaPneumoniamedicine.diseaseMultidrug-resistant pathogensPneumoniamultidrug-resistant pathogensMycosesBacteremiaAfricaEtiologyRISK-FACTORSimmunocompromiseAmericasbusinessClinical Infectious Diseases
researchProduct

Severe asthma: One disease and multiple definitions

2021

Abstract Introduction There is, so far, no universal definition of severe asthma. This definition usually relies on: number of exacerbations, inhaled therapy, need for oral corticosteroids, and respiratory function. The use of such parameters varies in the different definitions used. Thus, according to the parameters chosen, each patient may result in having severe asthma or not. The aim of this study was to evaluate how the choice of a specific definition of severe asthma can change the allocation of patients. Methods Data collected from the Severe Asthma Network Italy (SANI) registry were analyzed. All the patients included were then reclassified according to the definitions of U-BIOPRED,…

Pulmonary and Respiratory Medicinemedicine.medical_specialtySevere asthmaSevere asthmaImmunologyNiceDiseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioArticlePulmonary function testingInternal medicineBiological treatment; Classification; Definition; Severe asthmamedicineImmunology and AllergyRespiratory functioncomputer.programming_languageSevere asthma; Classification; Definition; Biological treatmentBiological therapiesbusiness.industrySettore MED/09 - MEDICINA INTERNADefinitionRC581-607ClassificationSevere asthma Classification Definition Biological treatmentBiological treatment Classification Definition Severe asthmaImmunologic diseases. AllergybusinessBiological treatmentcomputer
researchProduct

Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study

2016

BACKGROUND: Antibiotic resistance is a major global health problem and pathogens such as meticillin-resistant Staphylococcus aureus (MRSA) have become of particular concern in the management of lower respiratory tract infections. However, few data are available on the worldwide prevalence and risk factors for MRSA pneumonia. We aimed to determine the point prevalence of MRSA pneumonia and identify specific MRSA risk factors in community-dwelling patients hospitalised with pneumonia.METHODS: We did an international, multicentre study of community-dwelling, adult patients admitted to hospital with pneumonia who had microbiological tests taken within 24 h of presentation. We recruited investig…

Maleantibiotic resistancePrevalenceMRSAmedicine.disease_causepneumonia; antibiotic resistance; staphylococcus aureus; MRSAGlobal HealthCohort Studies0302 clinical medicineCommunity-acquired pneumoniaRisk FactorsRetrospective StudiePrevalenceCommunity-Acquired Infection030212 general & internal medicineeducation.field_of_studyCross InfectionRespiratory tract infectionsMethicillin-Resistant Staphylococcus aureuStaphylococcal InfectionsHospitalsCommunity-Acquired InfectionsInfectious DiseasesInfectious diseasesFemaleHumanMethicillin-Resistant Staphylococcus aureusstaphylococcus aureusmedicine.medical_specialtyPopulationAdmissionstaphylococcus aureuSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesHospitalInternal medicinemedicineHumanspneumoniaRisk factoreducationIntensive care medicineStaphylococcal InfectionRetrospective StudiesAgedbusiness.industryRisk FactorOdds ratioPneumoniamedicine.diseaseMethicillin-resistant Staphylococcus aureusPneumonia030228 respiratory systemMethicillin ResistanceCohort Studiebusiness
researchProduct

Nerve ablation after bronchial thermoplasty and sustained improvement in severe asthma

2017

Abstract Background Bronchial thermoplasty (BT) is a non-pharmacological intervention for severe asthma whose mechanism of action is not completely explained by a reduction of airway smooth muscle (ASM). In this study we analyzed the effect of BT on nerve fibers and inflammatory components in the bronchial mucosa at 1 year. Methods Endobronchial biopsies were obtained from 12 subjects (mean age 47 ± 11.3 years, 50% male) with severe asthma. Biopsies were performed at baseline (T0) and after 1 (T1), 2 (T2) and 12 (T12) months post-BT, and studied with immunocytochemistry and microscopy methods. Clinical data including Asthma Quality of Life Questionnaire (AQLQ) and Asthma Control Questionnai…

MaleSevere asthmaBronchial biopsieBiopsymedicine.medical_treatmentVital CapacityGastroenterologyBronchial thermoplasty0302 clinical medicineBronchoscopyQuality of lifeForced Expiratory VolumeSubmucosa030212 general & internal medicinemedicine.diagnostic_testCD68Middle AgedNerve fiberAblationImmunohistochemistryResidual VolumeTreatment Outcomemedicine.anatomical_structureAsthma Control QuestionnaireFemaleResearch ArticleAdultPulmonary and Respiratory Medicinemedicine.medical_specialtyBronchiBronchial biopsiesNerve fibersRespiratory MucosaSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesInternal medicineBronchoscopymedicineHumansAgedAsthmalcsh:RC705-779Bronchial thermoplastybusiness.industryTotal Lung Capacitylcsh:Diseases of the respiratory systemmedicine.diseaseAsthmarespiratory tract diseases030228 respiratory systembusinessBMC Pulmonary Medicine
researchProduct

Quality standards for the management of bronchiectasis in Italy: A national audit

2016

Although historically considered a neglected disease, bronchiectasis has become a disease of renewed interest over recent decades in light of an increase in prevalence and a substantial burden on healthcare systems. In 2010, the British Thoracic Society (BTS) published guidelines on the management of bronchiectasis in adults, along with specific quality standards. To date, these represent the only quality standards available in Europe. These have been tested over a number of years in the UK with progressive improvements in the standard of care. No national guidelines are available in Italy and no indications on which guideline should be followed have been given by the Italian Society of Res…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtybronchiectasismedia_common.quotation_subjectSymptom Flare UpMedical auditSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciences0302 clinical medicinemedicinePrevalenceHumansQuality (business)Pseudomonas Infections030212 general & internal medicineIntensive care medicineNational auditmedia_commonAgedMedical AuditBronchiectasisbusiness.industryMedicine (all)Middle Agedmedicine.diseaseSymptom Flare UpAnti-Bacterial AgentsPatient Care Management030228 respiratory systemItalyNeeds assessmentPseudomonas aeruginosaFemalebusinessMedicine (all); Pulmonary and Respiratory MedicineNeeds Assessment
researchProduct

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life

2021

Abstract Background and aims Severe asthma is burdened by frequent exacerbations and use of oral corticosteroids (OCS) which worsen patients’ health and increase healthcare spending. Aim of this study was to assess the clinical and economic effect of adding mepolizumab (MEP) for the treatment of these patients. Methods Patients >18 years old, referred to 8 asthma clinics, starting MEP between May 2017 and December 2018, were enrolled and followed-up for 12 months. Information in the 12 months before mepolizumab were collected retrospectively. The evaluation parameters included: OCS use, number of exacerbations/hospitalizations, concomitant therapies, comorbidity, and annual number of workin…

OR Odds RatioPediatricsSevere asthmaExacerbationAnti IL-5; Comorbidities; Mepolizumab; OCS; Pharmacoeconomics; Severe asthmagastroesophageal reflux diseaseSettore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIOICS inhaled corticosteroidRate ratioOCS Oral Corticosteroidslaw.inventionComorbiditiesLAMA long acting muscarinic antagonist0302 clinical medicineRandomized controlled trialfractional nitric oxideInterquartile rangelawlong acting beta 2 agonistOdds RatioImmunology and AllergyRR Rate Ratio030223 otorhinolaryngologyPharmacoeconomicLOS Length of stayLOSIQRLAMAMEP MepolizumabORCISD Standard DeviationMEPPharmacoeconomicsACT Asthma Control TestComorbiditieCI Confidence Intervalsmedicine.druglcsh:Immunologic diseases. AllergyPulmonary and Respiratory Medicinemedicine.medical_specialtyinterquartile rangelong acting muscarinic antagonistImmunologyLABALABA long acting beta 2 agonistComorbidities Mepolizumab OCS Pharmacoeconomics Severe asthma Anti IL-5RRArticleRate Ratiochronic obstructive pulmonary disease03 medical and health sciencesPharmacoeconomicsOCS Oral CorticosteroidAsthma Control TestConfidence IntervalsFeNO fractional nitric oxideRCTs Randomized Controlled TrialmedicineCOPDGERD gastroesophageal reflux diseaseFeNOIQR interquartile rangeMepolizumabSDAsthmaRCTsOral Corticosteroidsbusiness.industryGERDmedicine.diseaseICS inhaled corticosteroidsACTComorbidityRandomized Controlled TrialsCI Confidence IntervalRCTs Randomized Controlled TrialsOCSCOPD chronic obstructive pulmonary disease030228 respiratory systemICSStandard DeviationLength of stayAnti IL-5inhaled corticosteroidslcsh:RC581-607businessMepolizumab
researchProduct

Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendation…

2020

An accurate knowledge of the epidemiology of community-acquired pneumonia (CAP) is key for selecting appropriate antimicrobial treatments. Very few etiological studies assessed the appropriateness of empiric guideline recommendations at a multinational level. This study aims at the following: (i) describing the bacterial etiologic distribution of CAP and (ii) assessing the appropriateness of the empirical treatment recommendations by clinical practice guidelines (CPGs) for CAP in light of the bacterial pathogens diagnosed as causative agents of CAP. Secondary analysis of the GLIMP, a point-prevalence international study which enrolled adults hospitalized with CAP in 2015. The analysis was l…

Male0301 basic medicineMicrobiology (medical)medicine.medical_specialtyCommunity-acquired pneumonia030106 microbiologyAntimicrobial treatmentPrevalenceGuidelineSettore MED/10 - Malattie Dell'Apparato RespiratorioGuidelinesGlobal Healthmedicine.disease_causeImmunocompromised Host03 medical and health sciences0302 clinical medicineMedical microbiologyCommunity-acquired pneumoniaInternal medicineEpidemiologyStreptococcus pneumoniaePneumonia BacterialPrevalenceHumansMedicine030212 general & internal medicinePractice Patterns Physicians'AgedAged 80 and overbusiness.industryCorrectionGeneral MedicineGuidelineMiddle Agedmedicine.diseaseAnti-Bacterial AgentsCommunity-Acquired InfectionsHospitalizationPneumoniaInfectious DiseasesStreptococcus pneumoniaePractice Guidelines as TopicPseudomonas aeruginosaEtiologyOriginal ArticleFemaleGuideline Adherencebusiness
researchProduct

Additional file 1: of Atypical pathogens in hospitalized patients with community-acquired pneumonia: a worldwide perspective

2018

Table A: Tables with testing frequencies for specific atypical pathogens across continents (A1: Testing frequencies for C. pneumoniae across continents; A2: Testing frequencies for M. pneumoniae across continents; A3: Testing frequencies for L. pneumophila across continents).- Brief description of the data: a table in three parts reporting data about frequency of testing for different atypical pathogens across different continents. (DOC 50â kb)

researchProduct